Objectives: Recently, 2 independent studies reported that a rare missense variant, rs75932628 (R47H), in exon 2 of the gene encoding the "triggering receptor expressed on myeloid cells 2" (TREM2) significantly increases the risk of Alzheimer disease (AD) with an effect size comparable to that of the APOE e4 allele.
(i.e., an increase in AD risk conferred by the minor T allele) association with AD. We also performed conditional logistic regression to report the odds ratio (OR) as an informative parameter for comparing our results with those from previous studies. METHODS AD study cohort details and genotype generation. For the purpose of this study, we utilized several large sample collections with more than 9,300 individuals originating from both family-based and case-control datasets. We first genotyped rs75932628 in 2 family-based study samples: National Institute of Mental Health (NIMH) AD Genetics Initiative Study Family Sample, 12, 13 and the National Institute on Aging Genetics Initiative for Late Onset Alzheimer's Disease Family Study Sample 14 (NIA-LOAD) datasets. In addition, rs75935628 was also genotyped in the German Study on Ageing, Cognition and Dementia in Primary Care Patients (AgeCoDe) case-control samples. [15] [16] [17] Furthermore, rs75932628 genotypes were imputed in 3 publicly available GWAS datasets, GlaxoSmithKline (GSK), the Alzheimer's Disease Neuroimaging Initiative (ADNI), and the Translational Genomics Research Institute series 2 (TGEN2), which were not analyzed in the previous studies.
Family-based replication assessment by direct genotyping.
The portion of the NIMH AD family sample analyzed in this study consisted of 410 Caucasian families containing 917 affected (average age at onset 72 6 8.3 years, range 41-93) and 199 unaffected subjects (average age at last cognitive examination 78 6 9.4 years, range 49-100). All NIMH families were prescreened for mutations in the known early-onset familial AD (i.e., APP, PSEN1, or PSEN2) or frontotemporal dementia (i.e., MAPT, GRN, TARDBP, VCP, or CHMP2B) genes, resulting in an exclusion of 11 families from analysis. The NIA-LOAD familial cohort contained 517 Caucasian families with 860 affected (average age at onset 73 6 7.8 years, range 43-99) and 1,036 unaffected subjects (average age at last cognitive examination 65 6 9.9 years, range 50-100). To reduce the potential of diagnostic misclassification, we excluded unaffected subjects who were younger than 49 years of age at last cognitive examination from the family-based analyses. Both family cohorts included primarily sibling pairs. The NIMH contained 105 families with at least one sibling with an age at onset younger than 65 years, whereas the NIA-LOAD contained 92 families with one unaffected subject younger than 65 years. In addition, we genotyped the unrelated case-control portion of NIA-LOAD that included 378 cases and 686 controls. Note that this dataset was included in the original study, 8 but limited to imputed genotypes and not by direct genotyping.
Case-control replication assessment by direct genotyping or imputation. In addition to direct genotyping in the familybased studies, we imputed rs75932628 in 3 case-control cohorts: the GSK, ADNI, and TGEN2 utilizing IMPUTE2 18, 19 and the latest 1000 Genome project (phase I) reference panel. The imputation information quality scores for the GSK, ADNI, and TGEN2 cohorts were 0.30, 0.37, and 0.71, respectively. In addition, rs75932628 was determined by direct genotyping (using the MassARRAY system on a Sequenom Compact matrix-assisted laser desorption/ionization time-of-flight instrument [Sequenom Inc., San Diego, CA]) in 936 patients with AD and 923 healthy controls from Germany (here collectively summarized as "Bonn cohort"). [15] [16] [17] See the table for a summary of demographic characteristics of all datasets included in this study.
Standard protocol approvals, registrations, and patient consents. Informed consent was provided by all participants, and research approval was established by the relevant institutional review boards for each study cohort.
Statistical analyses. A family-based association test (FBAT)
approach was used to test for over-or undertransmission (i.e., risk or protection) of the minor allele in affected offspring as implemented in the PBAT 20,21 (version 3.6) software. Conditional logistic regression stratified by family was used to estimate the OR of the underlying risk effects in the family-based datasets. Because OR estimates in the context of family studies are inherently difficult to estimate precisely, the ORs calculated here are displayed merely for informational purposes but are not included in the fixed-effect meta-analyses described below. To assess population substructure within the case-control studies, principal component analysis was performed using EIGENSTRAT. 22 Allelic association analysis was performed as implemented in SNPTEST v2 23 for the case-control datasets with a logistic regression model adjusting for sex, age, and the first 3 principal components determined by EIGENSTRAT. Similarly, logistic regression adjusting for sex, age, and APO e4 status was used to estimate the OR and standard error in the case-control sample from Bonn. To aggregate data across the datasets analyzed here, we performed 2 types of meta-analyses: first, to estimate the overall level of statistical significance of the association evidence in our study, we performed a p value-based meta-analysis (using the METAL software 24 ) across all family-based and case-control datasets. For this purpose, we used the 2-tailed p values for each dataset weighted by their standard error. Second, to estimate the size of the underlying risk effect, we performed fixed-effect meta-analyses limited to the case-control samples only, given the above-mentioned uncertainties inherent in OR estimations derived from family data. Because the aim of this study was to specifically assess whether or not the minor T allele at rs75932628 increases the risk of AD, all reported studyspecific p values are 1-tailed (2-tailed values are used for the meta-analyses; see above). We estimated the power of our study by utilizing the "Genetic Power Calculator." 25 Combining all datasets, power to detect an allelic OR of 1.7 (i.e., the lowest 95% confidence bound suggested in the original study 8 ) at minor allele frequency (MAF) 0.004 (i.e., the median MAF observed in unaffected individuals here) at a 5 0.05 and a disease prevalence of 20% exceeds 80%.
RESULTS
Family-based association analyses. Family-based association analysis of experimentally determined genotypes in both the NIMH and NIA-LOAD cohorts provided independent support of an increase in AD risk conferred by the minor T allele at rs75932628, albeit at differing significance levels. In the NIMH cohort, there were 12 FBAT informative families (defined as those with at least one heterozygous parent) yielding a 1-tailed p value of 0.004 (table) , with an OR of 4.9 (95% confidence interval [CI] 1.18-20.83), which was comparable to previous studies. 8, 9 With an OR of 3.03 (95% CI 0.51-18.0), based on 7 FBAT informative families, the NIA-LOAD family cohort's effect estimate pointed in the same direction, but did not reach statistical significance (table), likely because of insufficient sample size.
Rare variant (burden) family-based association analysis in NIMH. We also assessed the potential effects of other rare variants in exon 2 of TREM2 on AD as suggested in the original report. 8 For this purpose, 410 probands from the NIMH family sample collection were resequenced in the TREM2 exon 2 region. Twenty-five nuclear families whose probands carried rare functional variants (a total of 65 affected and 17 unaffected subjects) were resequenced in the follow-up step. To perform "burden" analysis on 4 missense single nucleotide polymorphisms (SNPs) (rs75932628, rs143332484, rs2234253, and rs200392967) in exon 2 of TREM2 identified by our sequencing efforts, we based our statistical analysis on the rare variant extension of FBAT 26, 27 (version 2.0.4 beta). Based on the MAF of the subset of unrelated probands (n 5 25) in our follow-up sample, SNPs with MAF ,0.08 (arbitrarily chosen) were considered as rare variants; rs75932628-T was the most common of the 4 SNPs with a MAF 5 0.19. As expected, this higher MAF (0.19) in rs75932628-T frequency across all members of this subsample enriched for the minor allele is much higher than in the datasets overall (or the general population). Two options are available in FBAT's rare variant approach, such that each variant can contribute (1) equally (unweighted) or (2) unequally (weighted) to the rare variant statistic. In the latter option, each contributing SNP was inversely weighted, by the square root of (n 3 f 3 [1 2 f]), were n is the number of informative families and f is the MAF of the SNP. Thus, when weighting a set of SNPs, the contribution from the most common variant (here: rs75932628) was downweighted, while the contributions from other rare variants were upweighted. Setting the 4 SNPs to contribute equally, the contribution from rs75932628 dominated (1-tailed p value for the burden statistic 5 4.8 3 10 24 ). However, using the weighted option, the signal from the rare variants did not improve the strength of the association: 1-tailed p 5 1.8 3 10 23 .
Overall, burden analysis of rare variants in exon 2 of TREM2 in a subset of the NIMH cohort corroborated the rs75932628 association with AD risk observed in the entire Caucasian portion of the NIMH cohort. figure) . A p value-based meta-analysis combining all available data generated here, i.e., from the 2 family-based and 5 case-control datasets using METAL, suggests that the association between the minor T allele at rs75932628 and AD risk is statistically significant overall (z score 2.978, p value 5 0.0029; table) . DISCUSSION The results from our extensive analyses of 9,344 subjects using both family-based and casecontrol designs provide additional independent evidence supporting the previously reported association between the T allele at SNP rs75932628 in TREM2 with increased AD risk. However, the risk effect estimated here (OR 5 1.67) is considerably smaller than those reported in the previous studies: OR 5 2.9, 8 OR 5 4.5, 9 and OR 5 4.05 10 (specific effect size is not reported in one previous study 11 ). The relatively low quality of the genotype imputation (information score ,0.40) in the GSK and ADNI studies could contribute to this difference, although imputation uncertainty is accounted for in the association statistics. We also note that 4 of the 7 datasets (64% of the total subjects) included in our meta-analysis were directly genotyped. Thus, we believe the OR calculated in our meta-analysis remains largely reliable. This is also supported by analyses excluding the GSK and ADNI datasets, which reduced the OR estimates even further, although not statistically so (OR 5 1.43, 95% CI 0.90-2.28). To date, the NIMH and NIA-LOAD cohorts are the first family-based datasets to independently show evidence for the association between the minor T allele at rs75932628 in TREM2 and increased risk of AD, although the penetrance in the NIMH and NIA-LOAD cohort differed substantially (97% vs 61%, respectively). Note that although all controls in our study were deemed as "cognitively healthy" at the time of last examination, this status could possibly change over time, potentially leading to a reduction in power (and possibly underestimation of OR and statistical significance) in our analyses. While our data suggest that the association between rs75932628 and AD risk is most likely genuine, the combination of a modest effect size and very low MAF posits that this association finding bears very little epidemiologic relevance for the population at large (unlike the other known common AD risk alleles). At the same time, the penetrance of rs75932628 on AD risk is too small to be clinically meaningful to the individual (unlike any of the known early-onset AD-causing mutations in APP, PSEN1, and PSEN2). TREM2 shares its tiny population impact with the effects of the even lower prevalence, early-onset AD mutations in APP, PSEN1, and PSEN2. However, these latter mutations in APP, PSEN1, and PSEN2 are disease-causing and strike essentially with complete penetrance, making them reliable prognostic and diagnostic markers for individual patients or families. This characteristic is not shared with the R47H variant reported for TREM2.
TREM2 serves as a receptor in the innate immune system and is upregulated in microglia surrounding senile plaques in older APP23 mice 28 and CRND8 transgenic mice (expressing mutant KM670/671NL and V717F APP). 9 TREM2 also promotes the phagocytosis and clearance of b-amyloid protein. 29 Similarly, another LOAD gene, CD33, 2 is expressed in microglia and has been shown to inhibit microglial uptake and clearance of b-amyloid. 30 The CD33 variant, rs3865444, which protects against AD, is associated with reduced CD33 microglial expression, and inactivation of CD33 in mice leads to reduced b-amyloid levels. 30 Together, the genetic and transgenic mouse findings support both that TREM2, similar to CD33, is a critical player in AD pathogenesis and a promising target for therapeutic treatment based on enhancement of b-amyloid uptake and clearance.
Based on our analysis, TREM2 harbors a lowfrequency variant associated with AD risk that bears very little epidemiologic relevance for the population at large. Given the low frequency of R47H and overall modest effects on risk for AD (OR 5 1.67), this variant would also possess minimal clinical utility as a predictor or diagnostic for AD. Nonetheless, further elucidation of how TREM2 and CD33 regulate b-amyloid uptake and clearance will be important for further development of these targets in the quest to effectively treat and prevent AD. 
